The Core of this application consists of two major components. In the first component, support is requested for continued operation of the transgenic mouse facility which has been an integral part of this program since its inception. This facility provides for embryo microinjections and the surgery required for generating transgenic mice;, breeds and produces pseudopregnant recipient mice for implantation of injected murine embryos; and provides help in the protocols for injections of pregnant mare's serum and chorionic gonadotrophin for superovulation. During the past five years, this facility, has been extensively used by Drs. McDevitt. Davis, Weissman and Parnes and during the coming five years will be used by these investigators as well as by Drs. Jones and Goodnow in a series of transgenic mouse lines described in the Core proposal. The second component of the Core facility is the fluorescence activated cell sorter, which provides support to the laboratories of all the investigators in this program. This is a state of the art facility run by Drs. Herzenberg and Parks. It includes two multiparameter FACS sorters. a four parameter FACSscan flow cytometer and extensive computing facilities required for the analysis of data coming from analytical runs on the sorter. This is a unique resource which has provided excellent technical support to all of the laboratories in the program as well as to a number of other laboratories at Stanford Medical School. This facility has used been used very heavily by the investigators on this grant and all of the proposed projects require continued high usage for the experiments described.

Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1996
Total Cost
Indirect Cost
Pogue, S L; Goodnow, C C (2000) Gene dose-dependent maturation and receptor editing of B cells expressing immunoglobulin (Ig)G1 or IgM/IgG1 tail antigen receptors. J Exp Med 191:1031-44
Frank, G D; Parnes, J R (1998) The level of CD4 surface protein influences T cell selection in the thymus. J Immunol 160:634-42
Zhang, X L; Seong, R; Piracha, R et al. (1998) Distinct stage-specific cis-active transcriptional mechanisms control expression of T cell coreceptor CD8 alpha at double- and single-positive stages of thymic development. J Immunol 161:2254-66
Messika, E J; Lu, P S; Sung, Y J et al. (1998) Differential effect of B lymphocyte-induced maturation protein (Blimp-1) expression on cell fate during B cell development. J Exp Med 188:515-25
Townsend, S E; Goodnow, C C (1998) Abortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo. J Exp Med 187:1611-21
Akkaraju, S; Canaan, K; Goodnow, C C (1997) Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells. J Exp Med 186:2005-12
Akkaraju, S; Ho, W Y; Leong, D et al. (1997) A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immunity 7:255-71
Reich, Z; Altman, J D; Boniface, J J et al. (1997) Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins. Proc Natl Acad Sci U S A 94:2495-500
Conboy, I M; DeKruyff, R H; Tate, K M et al. (1997) Novel genetic regulation of T helper 1 (Th1)/Th2 cytokine production and encephalitogenicity in inbred mouse strains. J Exp Med 185:439-51
Fournier, S; Rathmell, J C; Goodnow, C C et al. (1997) T cell-mediated elimination of B7.2 transgenic B cells. Immunity 6:327-39

Showing the most recent 10 out of 77 publications